Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade B 61.13 -2.81% -1.77
RARE closed down 2.81 percent on Friday, February 14, 2020, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical RARE trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Earnings Movers Other 0.00%
Outside Day Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Overbought Stochastic Strength -2.81%
Up 3 Days in a Row Strength -2.81%
Up 4 Days in a Row Strength -2.81%
Up 5 Days in a Row Strength -2.81%
Overbought Stochastic Strength -2.78%
Up 3 Days in a Row Strength -2.78%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Rare Diseases Enzyme Replacement Therapy Biologics Rare And Ultra Rare Diseases

Is RARE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 74.5
52 Week Low 35.41
Average Volume 519,770
200-Day Moving Average 51.60
50-Day Moving Average 50.91
20-Day Moving Average 58.22
10-Day Moving Average 60.13
Average True Range 2.51
ADX 33.83
+DI 31.15
-DI 16.07
Chandelier Exit (Long, 3 ATRs ) 56.71
Chandelier Exit (Short, 3 ATRs ) 58.55
Upper Bollinger Band 64.45
Lower Bollinger Band 51.99
Percent B (%b) 0.73
BandWidth 21.40
MACD Line 3.08
MACD Signal Line 2.98
MACD Histogram 0.0999
Fundamentals Value
Market Cap 2.6 Billion
Num Shares 42.6 Million
EPS -6.74
Price-to-Earnings (P/E) Ratio -9.07
Price-to-Sales 16800.34
Price-to-Book 4.53
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 66.89
Resistance 3 (R3) 67.29 65.76 65.93
Resistance 2 (R2) 65.76 64.30 65.57 65.61
Resistance 1 (R1) 63.45 63.39 62.69 63.05 65.29
Pivot Point 61.92 61.92 61.54 61.73 61.92
Support 1 (S1) 59.61 60.46 58.85 59.21 56.97
Support 2 (S2) 58.08 59.55 57.89 56.65
Support 3 (S3) 55.77 58.08 56.33
Support 4 (S4) 55.37